META has officially been welcomed into Johnson & Johnson Innovation – JLABS, the global healthcare giant’s premier life science incubator, becoming one of its resident companies. This marks a significant milestone in META’s corporate history.

Founded in August 2021, META’s founding team hails from Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center, two world-leading research hospitals, with deep expertise in the emerging field of immunometabolism.

Johnson & Johnson Innovation – JLABS is a global network of open innovation ecosystems, enabling innovators to deliver life-saving, life-enhancing health solutions to patients worldwide faster. As a leader in innovation, JLABS is open to entrepreneurs in pharmaceuticals, medical devices, consumer health, and health technology, helping them bring healthcare solutions to patients and consumers.

By joining JLABS, META embarks on an upgraded innovation paradigm. Leveraging JLABS’ global innovation network spanning North America, Europe, and Asia, META will deeply integrate diverse resources to accelerate the development of its first-in-class drug candidates.